The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb
Jack Bibby, Yauba Saidu, Ama Umesi, Ngozi Moneke-Anyanwoke, Adedapo O Bashorun, Mariama Badjie Hydara, Ikechukwu Adigweme, Jane U Adetifa, Michael Okoye, Elishia Roberts, Ralf Clemens, Ananda S Bandyopadhyay, Abdul K Muhammad, Sarah Mulwa, Michael Royals, Courtney Jarrahian, David Jeffries, Beate Kampmann, Ed Clarke, Jack Bibby, Yauba Saidu, Ama Umesi, Ngozi Moneke-Anyanwoke, Adedapo O Bashorun, Mariama Badjie Hydara, Ikechukwu Adigweme, Jane U Adetifa, Michael Okoye, Elishia Roberts, Ralf Clemens, Ananda S Bandyopadhyay, Abdul K Muhammad, Sarah Mulwa, Michael Royals, Courtney Jarrahian, David Jeffries, Beate Kampmann, Ed Clarke
Abstract
The immunogenicity of fractional (one-fifth, 0.1 mL) intradermal doses of the inactivated poliovirus vaccine (ID fIPV) is positively correlated with the size of the intradermal fluid bleb. Training of vaccinators for campaign and routine ID fIPV administration should focus on generating an 8- to 10-mm bleb with each injection. Clinical Trials Registration NCT01847872.
Keywords: inactivated poliovirus vaccine; intradermal; polio.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.
References
- Global Polio Eradication Initiative. The introduction of IPV, the OPV switch, and risk mitigation information. Available at: . Accessed 1 January 2017.
- Fractional-dose inactivated poliovirus vaccination campaign, Telangana state, India, June 2016. Wkly Epidemiol Rec 2016; 91: 397–403.
- India Expert Advisory Group. An interim meeting of the mini India Expert Advisory Group (IEAG) for polio eradication. Conclusions and Recommendations. Delhi, India: IEAG, 2016.
- World Health Organization. 15th WHO/UNICEF consultation with OPV and IPV manufacturers and national regulatory authorities. Available at: . Accessed 1 January 2017.
- Meeting of the Strategic Advisory Group of Experts on immunization, October 2016—conclusions and recommendations. Wkly Epidemiol Rec 2016; 91:561–82.
- Clarke E, Saidu Y, Adetifa JU et al. . Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Health 2016; 4:e534–47.
- World Health Organization. Manual for the virological investigation of polio. WHO/EPI/GEN/97.01. Geneva, Switzerland: WHO, 2004.
- Altman DG, Gardner MJ. Calculating confidence intervals for regression and correlation. Br Med J (Clin Res Ed) 1988; 296:1238–42.
- Resik S, Tejeda A, Mach O et al. . Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity. Vaccine 2015; 33:5873–7.
Source: PubMed